Boston ScientificMEX:BSX -1.64%85 PE Ratio (TTM) is 17.92 as of Jul. 09, 2026, which is 72% below its 10-year median of 64.91. GuruFocus rates MEX:BSX with a GF Score™ of 85/100 and a GF Value™ of MXN1,851.81 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 435 Medical Devices & Instruments companies, Boston Scientific ranks better than 65.98% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-09), Boston Scientific's share price is
MXN782.01.
Boston Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN43.63. Therefore, Boston Scientific's PE Ratio (TTM) for today is 17.92.
Good Sign:
Boston Scientific Corp stock PE Ratio (=18.75) is close to 5-year low of 18.51.
The historical rank and industry rank for Boston Scientific's PE Ratio (TTM) or its related term are showing as below:
MEX:BSX'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 8.18 Med: 64.91 Max: 470.86
Current: 18.75
During the past 13 years, the highest PE Ratio (TTM) of Boston Scientific was 470.86. The lowest was 8.18. And the median was 64.91.
MEX:BSX's PE Ratio (TTM) is ranked better than 65.98% of 435
companies
in the Medical Devices & Instruments industry
Industry Median: 26.37
vs MEX:BSX: 18.75
During the past 12 months, Boston Scientific's average EPS without NRIGrowth Rate was 14.80% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 21.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 23.10% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 10.50% per year.
During the past 13 years, Boston Scientific's highest 3-Year average EPS without NRI Growth Rate was 123.60% per year. The lowest was -70.30% per year. And the median was 16.20% per year.
Boston Scientific's EPS (Basic) for the
three
months ended in Mar. 2026 was MXN16.23.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN43.86.
Boston Scientific (MEX:BSX) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Boston Scientific PE Ratio (TTM) Related Terms
Boston Scientific PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Boston Scientific's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BSX vs EW, GEHC, MDT: PE Ratio (TTM) Comparison
For the Medical Devices subindustry, Boston Scientific's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific PE Ratio (TTM) vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Boston Scientific's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Boston Scientific's Share Price of today is MXN782.01.
Boston Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN43.63.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Boston Scientific (MEX:BSX) has a PE Ratio (TTM) of 17.92 as of Jul. 09, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Boston Scientific and its competitors. This is 72% below median its historical median of 64.91. Over the past decade, Boston Scientific's PE Ratio (TTM) has ranged from 8.18 to 470.86. According to the industry distribution chart, Boston Scientific ranks #148 out of 435 companies in the Medical Devices & Instruments industry, placing it in the top 34%.
Is Boston Scientific's PE Ratio (TTM) too high?
Boston Scientific's current PE Ratio (TTM) of 17.92 is 72% below median its 10-year median of 64.91. Over the past 10 years, this metric has ranged from a low of 8.18 to a high of 470.86. The Medical Devices & Instruments industry median PE Ratio (TTM) is 26.37. Boston Scientific's value of 17.92 is 32% below this industry median. Based on the distribution chart, Boston Scientific ranks #148 out of 435 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boston Scientific has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's PE Ratio (TTM) compare to EW and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #148 out of 435 companies for PE Ratio (TTM). This puts Boston Scientific in the upper half of its industry. The industry median PE Ratio (TTM) is 26.37. Boston Scientific's value of 17.92 is 32% below this benchmark. Historically, Boston Scientific's own PE Ratio (TTM) has ranged from 8.18 to 470.86 over the past decade. While the company's 10-year median is 64.91 vs. the industry median of 26.37, Boston Scientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Devices & Instruments company?
The median PE Ratio (TTM) among Medical Devices & Instruments companies is 26.37, based on 435 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boston Scientific's current PE Ratio (TTM) of 17.92 is 32% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Boston Scientific and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio (TTM) is 26.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boston Scientific's current PE Ratio (TTM) is 17.92, which is 72% below median its own 10-year median of 64.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,851.81, compared to a current price of MXN782.01 — trading 57.8% below its estimated fair value. The current PE Ratio (TTM) is 17.92, which is 72% below median its 10-year median of 64.91 and 32% below the Medical Devices & Instruments industry median of 26.37. Boston Scientific's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current PE Ratio (TTM) is 17.92 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (MEX:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of MXN782.01 is trading 57.8% below its estimated GF Value™ of MXN1,851.81.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for MEX:BSX:
PE Ratio (TTM): 17.92 (72% below median its 10-year median of 64.91)
GF Value™: MXN1,851.81 vs. price of MXN782.01 (57.8% below fair value)
Industry Position: 32% below the Medical Devices & Instruments median (#148 of 435)
No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
85GF Score
Get the complete analysis for MEX:BSX
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BSX has been successfully added to your 
